Pharmacokinetically guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients.

Authors	Simon E Koele, Stijn W van Beek, Anthonie J van der Wekken, Berber Piet, Michel M van den Heuvel, Rob Ter Heine
Journal	British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 88 Issue 8 Pg. 3920-3921 (08 2022) ISSN: 1365-2125 [Electronic] England
PMID	35350084 (Publication Type: Letter, Comment)
Chemical References	Organophosphorus Compounds Protein Kinase Inhibitors Pyrimidines brigatinib
Topics	Carcinoma, Non-Small-Cell Lung (drug therapy) Humans Lung Neoplasms (drug therapy) Organophosphorus Compounds Protein Kinase Inhibitors (therapeutic use) Pyrimidines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!